---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-119494"
form_type: "8-K"
ticker: "IPSC"
cik: "0001850119"
company_name: "Century Therapeutics, Inc."
filed_at: "2025-12-09T23:59:59+00:00"
generated_at: "2026-05-16T13:50:10.946919+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Century Therapeutics appoints Dr. Murphy and Dr. Lee to Board, expanding from six to eight members

## Summary
- Board expanded from six to eight directors; Dr. Murphy (Class III, term to 2027) and Dr. Lee (Class II, term to 2026) appointed.
- Dr. Murphy brings life science investment experience; Dr. Lee brings corporate development and CFO background from biotech firms.
- Each new director received an initial option grant of 88,000 shares vesting over 36 months and a $40,000 annual cash retainer.
- Dr. Murphy joins Compensation and Nominating/Governance Committees; Dr. Lee joins Audit and Compensation Committees.
- Appointments effective December 9, 2025; both deemed independent under Nasdaq rules.

## SEC filing metadata
- accession: 0001104659-25-119494
- form_type: 8-K
- ticker: IPSC
- cik: 0001850119
- company_name: Century Therapeutics, Inc.
- filed_at: 2025-12-09T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850119/000110465925119494/0001104659-25-119494-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850119/000110465925119494/tm2532966d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-119494
- JSON: https://secwatch.observer/filing/0001104659-25-119494.json
- Plain text: https://secwatch.observer/filing/0001104659-25-119494.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.